Blackstone Ventures and Lattice Biologics Propose Merger

- August 14th, 2015

Lattice Biologics has announced that it has entered into a letter of intent with Blackstone Ventures, with Blackstone acquiring all issued and outstanding securities of Lattice. This is would be a reverse takeover, with the Lattice taking over Blackstone and the combined company being listed on the TSX Venture Exchange.

Lattice Biologics has announced that it has entered into a letter of intent with Blackstone Ventures, with Blackstone acquiring all issued and outstanding securities of Lattice. This is would be a reverse takeover, with the Lattice taking over Blackstone and the combined company being listed on the TSX Venture Exchange.
According to the news release:

On closing of the Transaction, the stockholders of Lattice will receive 35,764,184 shares of Blackstone in exchange for all of the issued common stock of Lattice. As a result, former stockholders of Lattice will own approximately between 77% and 82% of Blackstone. These shares of Blackstone will be comprised of both shares and/or unlisted convertible, restricted voting shares.
Under the terms of the LOI and prior to closing of the Transaction, Blackstone will have completed two share consolidations (effectively being a combined 60:1 consolidation of Blackstone) and settled outstanding debt through the issuance of common shares.
Additionally, Lattice has convertible notes having an aggregate principal amount of USD $1,050,000 and is in the process of granting rights to acquire an aggregate of 1,500,000 common shares of Blackstone over a period of three years in consideration of services to be rendered up to and including members of Lattice’s Scientific Advisory Board.

Click here to read the entire news release.
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply